Navigation Links
Valeant Pharmaceuticals to Syndicate Incremental Term Loans
Date:11/30/2011

MISSISSAUGA, Ontario, Nov. 30, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced plans to syndicate $350 million of incremental term loans under its existing senior secured credit facilities to partially fund its previously announced acquisition of iNova.  The incremental term loans will mature in April 2016 and are expected to have terms that are consistent with the Company's existing $1.725 billion Term Loan A facility. The incremental term loans are expected to close in December 2011, subject to market and other customary conditions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
2. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
3. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
4. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
5. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
6. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
7. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
8. Valeant Pharmaceuticals to Present at Industry Conferences
9. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
10. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
11. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 2017 TapImmune, Inc. (NASDAQ: ... development of innovative peptide and gene-based immunotherapeutics for ... announced that it will participate in two upcoming ... Glynn Wilson , Chairman and CEO of TapImmune, ... clinical pipeline and partnering opportunities for its proprietary ...
(Date:3/22/2017)... 22, 2017 A new independent study ... the proven ultraviolet-C (UV-C) disinfection solution of choice ... Published in the March issue ... , the peer-reviewed study of UV-C disinfection systems ... General Hospital and Rochester General Hospital. According to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... University Orthopedics (UOI) today announced the ... Hand, Upper Extremity and Microvascular Surgery at Newport Hospital. Dr. Bragdon specializes in ... and Hand Surgery. , As the leader of comprehensive orthopedic care in ...
(Date:3/22/2017)... ... 22, 2017 , ... Last year, 43 million gallons of surplus milk was ... While excess dairy can be caused by several factors, one pharmaceutical company CEO ... to properly digest lactose, a sugar found in milk and milk products. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo ... Jersey and the New York metropolitan region, is embarking on a cooperative charity ... families. , At present, more than two and a half million children in ...
(Date:3/22/2017)... ... 22, 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, ... embarking on a combined charity effort with the Great Neck Breast Cancer Coalition to ... the Great Neck Breast Cancer Coalition has worked to support breast cancer patients in ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services to regional families and business owners, is joining the Teen Recovery Solutions ... in the area. , A growing number of Oklahoma teens and adolescents face ...
Breaking Medicine News(10 mins):